Lexicon Pharmaceuticals to Announce Topline Results From Phase 2b PROGRESS Study Evaluating Pilavapa.
Lexicon Pharmaceuticals, Inc. is set to share top-line results from the Phase 2b PROGRESS study evaluating pilavapadin (LX9211), an oral, non-opioid investigational AAK1 inhibitor in adult patients with moderate to severe diabetic peripheral neuropathic pain (DPNP). The study's findings are expected to provide valuable insights into the efficacy and safety of pilavapadin in treating this debilitating condition. Lexicon management will discuss the results on a conference call and webcast on Monday, March 3, 2025.
- The success of pilavapadin in clinical trials may mark a significant turning point in the treatment of DPNP, offering a new option for patients with limited treatment choices.
- Will the approval of pilavapadin lead to increased pressure on pharmaceutical companies to prioritize innovation in pain management research, potentially driving breakthroughs in this crucial area?